BofA Downgrades Biohaven to Underperform, Slashes PT to $11

Bank of America (BofA) downgraded Biohaven Pharmaceutical (BHVN) to 'Underperform' from 'Neutral' and slashed the price target to $11, implying a potential downside of about 26% from the stock's previous close.

Rating Change Details

• Previous Rating: Neutral
• New Rating: Underperform
• New Price Target: $11
• Downside Potential: Approximately 26% from last close

Analyst Rationale

BofA analysts did not provide specific reasons for the downgrade in the report published on Stocktwits. However, such downgrades often reflect concerns about growth prospects, competitive positioning, or regulatory challenges.

Context

Biohaven Pharmaceutical specializes in developing treatments for neurological disorders, including migraines. The stock has experienced volatility recently. No immediate reactions from other analysts have been reported.

What to Make of It

The downgrade by BofA signals a bearish outlook on the stock's near-term performance. Investors should watch for any company updates that could affect the price target.